The Week of

Researchers reported that an 80-year-old woman with advanced Alzheimer's disease experienced a temporary but dramatic improvement in communication, social engagement, and awareness after receiving a high dose of psilocybin.

While this was only a single patient and far from a cure, the findings raise intriguing questions about whether psychedelics could someday play a role in treating neurodegenerative diseases where meaningful breakthroughs have been hard to find.

It’s fascinating review, and you can read more about it here: https://jlsfund.substack.com/p/an-alzheimers-patient-experienced

Eli Lilly signed a new Alzheimer's licensing deal with Swedish biotech AlzeCure Pharma that could ultimately be worth more than $1 billion.

The agreement gives Lilly global rights to Alzstatin ACD680, an experimental therapy designed to reduce the production of amyloid-beta proteins believed to contribute to Alzheimer's disease. In addition to ACD680, the company also has additional programs targeting cognition, neurodegenerative diseases, traumatic brain injury, and chronic pain. Check it out: https://jlsfund.substack.com/p/alzecure-scores-a-major-win-with

FloBiotech announced a licensing agreement with UCLA Health for DDL-357, a small-molecule therapy targeting protective biological pathways involved in diseases such as Alzheimer's and Progressive Supranuclear Palsy (PSP).

Preclinical data showed the compound reduced phosphorylated tau levels by roughly 40% while also improving memory performance in disease models. Here’s more: https://www.biospace.com/press-releases/flobiotech-announces-agreement-with-ucla-health-to-advance-neurodegenerative-disease-therapeutics

Did you know that the modern story of ibogaine began with a 19-year-old heroin addict named Howard Lotsof?

In 1962, Lotsof took ibogaine expecting nothing more than a psychedelic experience. Instead, roughly 30 hours later, he discovered something unexpected: his withdrawal symptoms were gone, and he no longer craved heroin.

Intrigued, he shared the substance with several addicted friends, many of whom reported similar results. What started as an accidental discovery eventually led Lotsof to spend decades advocating for ibogaine research, filing patents, and collaborating with scientists studying its potential role in addiction treatment. Check it out: https://ibogainefinder.com/learn/ibogaine-howard-lotsof-addiction-discovery/